Kolexia
Lehmann Sylvain
Biologie médicale
Hôpital Saint-Éloi
Montpellier, France
316 Activités
762 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Maladie d'Alzheimer Démence Sclérose Maladies neurodégénératives Sclérose en plaques Inflammation Maladies à prions Maladie de Creutzfeldt-Jakob Angiopathie amyloïde cérébrale

Industries

Roche
10 collaboration(s)
Dernière en 2022
Lilly
5 collaboration(s)
Dernière en 2023
Biogen
4 collaboration(s)
Dernière en 2022
Adept Field Solutions
1 collaboration(s)
Dernière en 2020

Dernières activités

The free plasma amyloid Aβ /Aβ ratio predicts conversion to dementia for subjects with mild cognitive impairment with performance equivalent to that of the total plasma Aβ /Aβ ratio. The BALTAZAR study.
Neurobiology of disease   27 février 2024
Prospective 25-year surveillance of prion diseases in France, 1992 to 2016: a slow waning of epidemics and an increase in observed sporadic forms.
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin   16 décembre 2023
JR9 - OC A.6 - Sylvain LEHMANN
Youtube @ Filière FILSLAN   11 décembre 2023
Blood Neurofilament Levels Predict Cognitive Decline across the Alzheimer's Disease Continuum.
International journal of molecular sciences   11 décembre 2023
Use of dried blood spots for monitoring inflammatory and nutritional biomarkers in the elderly.
Clinical chemistry and laboratory medicine   24 novembre 2023
A sensitive high-resolution mass spectrometry method for quantifying intact M-protein light chains in patients with multiple myeloma.
Clinica chimica acta; international journal of clinical chemistry   20 novembre 2023
Generation of induced pluripotent stem cell lines IRMBi003-A and IRMBi003-B from a healthy donor to model Alzheimer's disease.
Stem cell research   11 novembre 2023
Biomarqueurs de la maladie d’Alzheimer : promesses et limites
Edimark   23 octobre 2023
Readthrough isoform of aquaporin-4 (AQP4) as a therapeutic target for Alzheimer's disease and other proteinopathies.
Alzheimer's research & therapy   11 octobre 2023
Establishment of induced pluripotent stem cells IRMBi005-A from a patient with sporadic Alzheimer's disease.
Stem cell research   25 septembre 2023